Julian Crump

• Reduced Time Limits for Filing Divisional Applications at the European Patent Office, Intellectual Property Alert (08.14.2009)
• Patentability of Dosage Regimens at the EPO and in the UK, Intellectual Property Advisory (07.16.2008)
• The London Agreement, Intellectual Property Alert (02.11.2008)
• EPO Gets Tough on Complex Applications, Intellectual Property Alert (01.10.2008)

• Quoted in Are IP Associations Failing Us?, Managing Intellectual Property (10.31.2012)
• Quoted in FICPI and It’s Campaign for Relevance: Project Orange, Managing Intellectual Property (10.31.2012)
• Richard G. Gervase and Julian Crump to moderate panel discussion at AdvaMed 2008 - The MedTech Conference, (09.23.2008)
• Mintz Levin Expands London Office to Accommodate Growing Corporate and Intellectual Property Practice, (09.18.2008)
• Mintz Levin Represents Novosom AG in Exclusive License Agreement with Isis Pharmaceuticals, Inc., (09.10.2008)
• Mintz Levin Advises SkyePharma PLC in Refinancing of Convertible Bonds, (09.08.2008)

Julian is Managing Partner of the firm’s London office. He is qualified as a Chartered Patent Attorney (CPA; 1993) in the UK and as a European Patent Attorney (EPA; 1995), having over 19 years’ experience in the profession.

Julian’s practice is focused on pharmaceuticals and medicinal chemistry, biochemistry, biotechnology, and medical devices, especially novel drug formulations, liposomes and other drug vehicles, new chemical entities, stem cells, protein micro-arrays and biomarkers, bio-informatics, stents, and diagnostic and therapeutic instruments. He has also gained substantial knowledge in other technical areas, including food technology, packaging, product-handling equipment, and aircraft seating systems. Julian acts for a diverse range of clients ranging from start-ups to multinational corporations.

He has extensive experience in proceedings before the European Patent Office (EPO), especially the conduct and representation of clients at oral proceedings before the Examining and Opposition Divisions, and before the Boards of Appeal. He also advises clients on the intellectual property (IP) aspects of licences and other technology transfer agreements and has performed a number of IP due diligence reviews for a variety of different clients, including investors as well as parties to prospective licensing and collaboration deals.

Julian is the author of numerous papers and presentations. He is also qualified as a Registered Trade Mark Attorney (1992) and registered as an authorised representative before the European Union’s Office for Harmonization in the Internal Market (Trade Marks and Designs).

Recognitions & Awards

• Gill Prize
• Ballantyne Prize

Professional & Community Involvement

• Secretary general (2006 – present), La Fédération Internationale des Conseils en Propriété Industrielle (the International Federation of Industrial Property Attorneys, FICPI)
• Reporter general (2003 – 2006), FICPI Work and Study Commission

Publications

• Reduced Time Limits for Filing Divisional Applications at the European Patent Office, Intellectual Property Alert (08.14.2009)
• Patentability of Dosage Regimens at the EPO and in the UK, Intellectual Property Advisory (07.16.2008)
• The London Agreement, Intellectual Property Alert (02.11.2008)
• EPO Gets Tough on Complex Applications, Intellectual Property Alert (01.10.2008)

• Quoted in Are IP Associations Failing Us?, Managing Intellectual Property (10.31.2012)
• Quoted in FICPI and It’s Campaign for Relevance: Project Orange, Managing Intellectual Property (10.31.2012)
• Richard G. Gervase and Julian Crump to moderate panel discussion at AdvaMed 2008 - The MedTech Conference, (09.23.2008)
• Mintz Levin Expands London Office to Accommodate Growing Corporate and Intellectual Property Practice, (09.18.2008)
• Mintz Levin Represents Novosom AG in Exclusive License Agreement with Isis Pharmaceuticals, Inc., (09.10.2008)
• Mintz Levin Advises SkyePharma PLC in Refinancing of Convertible Bonds, (09.08.2008)